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1. Introduction
Opioid analgesics are commonly and in most cases effectively used to manage chronic pain
of moderate to severe intensity. Apart from analgesia, opioids exert numerous adverse ef‐
fects, several of which impact the gastrointestinal (GI) tract. The chronic use of opioid anal‐
gesics in fact is commonly associated with adverse effects on the gastrointestinal tract. [1]
Opioid–induced bowel dysfunction (OIBD) comprises gastrointestinal symptoms such as
dry mouth, anorexia, gastroesophageal reflux (GERD), delayed digestion, abdominal pain,
flatulence, bloating, nausea, vomiting, and constipation with hard stool and incomplete
evacuation. Further, side effects from long–term opioid therapy may result in more serious
intestinal complications such as faecal impaction with overflow diarrhea and incontinence,
pseudo–obstruction (causing anorexia, nausea and vomiting), disturbance of drug absorp‐
tion, and urinary retention and incontinence. OIBD may also lead to inappropriate opioid
dosing and in consequence, insufficient analgesia. As a result, OIBD significantly deteriorate
patients’ quality of life and compliance with their treatment. Approximately one-third of pa‐
tients treated with opioid analgesics do not adhere to the prescribed opioid regimen or sim‐
ply quit the treatment due to OIBD symptoms [2].
Several strategies have been advocated to prevent or treat OIBD. Use of traditional laxatives
is limited by their effectiveness, yet conveys their own adverse effects. Other possibilities
comprise an opioid switch or changing the opioid administration route. New therapies now
target opioid receptors in the gut as they represent a main source of OIBD symptoms. A
combination of an opioid and opioid antagonist (oxycodone/naloxone) in prolonged release
tablets and purely peripherally acting opioid receptor antagonist (methylnaltrexone) availa‐
ble in subcutaneous injections are currently available treatment options. This chapter re‐
views the pathophysiological basis and possible treatment strategies for OIBD.
© 2013 Leppert; licensee InTech. This is a paper distributed under the terms of the Creative Commons
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2. Pathophysiological mechanism of opioid–induced bowel dysfunction
Opioids produce widespread effects throughout the gastrointestinal tract though several
central and peripheral mechanisms. Such effects are a mixture of inhibitory and excitatory
actions. Opioid peptides and their receptors are found throughout the gastrointestinal tract,
especially in the gastric antrum and proximal duodenum. The basis for OIBD is therefore
complex. The peripheral opioid effect on µ–opioid receptors in the gut wall likely plays a
major role, but central effects may also be important [3]. µ–opioid receptors at a high density
reside in neurons of myenteric and submucosal plexus and immune cells in the lamina
propria [4]. Opioid receptors (predominantly µ, also κ and δ) are located in the gut wall in
the myenteric plexus and in the submucosal plexus. The former are responsible for gut mo‐
tility and the latter for secretion. These µ–opioid receptors are activated in the wall of the
stomach, small and large intestine by both endogenous (e.g. enkephalins, endorphins and
dynorphins) and exogenous (e.g. morphine, oxycodone, methadone) opioids and modify
gastrointestinal function. Activation of µ–opioid receptors inhibits excitatory and inhibitory
neural pathways within the enteric nervous system that coordinates motility. Inhibition of
excitatory neural pathways depresses peristaltic contractions. On the other hand, the block‐
ade of inhibitory neural pathways increases gut muscle activity, elevates resting muscle
tone, and results in spasm and non–propulsive motility patterns. These mechanisms give
rise to delayed gastric emptying and slowed intestinal transit [5].
Activation of opioid receptors in the submucosa inhibits water and electrolyte secretion into
the gut lumen and increases fluid absorption from the intestine and accelerates blood flow
in the gut wall [6]. Opioids increase activity in the sympathetic nervous system and thereby
decrease secretion. Endocrine cells located in the epithelium also may play a role in regulat‐
ing motor activity and secretion in the gut. Interms of motility, peripheral µ–opioid recep‐
tors inhibit intestinal transit independent of central µ–opioid receptors [7]. Moreover,
opioids increase ileocaecal and anal sphincter tones and impair defecation reflex through re‐
duced sensitivity to distension and increased internal anal sphincter tone [8]. Morphine ad‐
ministration leads to sphincter contraction and to a decreased emptying of pancreatic juice
and bile [9], which may impair digestion. The anal sphincter dysfunction is an important
factor in the sensation of anal blockage [10,11].
The central mechanism of opioid effects on the gastrointestinal tract is supported by the re‐
sults of animal studies in which intracerebroventricular administration of morphine inhibit‐
ed GI propulsion [12]. This effect was reversed by intracerebroventricular administration of
naloxone [13] and vagotomy [14]. Intrathecal administration of morphine reduced gastro‐
duodenal motility while intramuscular morphine gave additional effects. Thus, it seems that
both central and peripheral opioid effects play a role in opioid GI effects [15]. The indirect
evidence of both central and peripheral components of opioid effects on bowel function may
be the observed 50–60% response rate to the treatment of OIBD with methylnaltrexone
(MNTX), which displays only peripheral µ–opioid receptor antagonist effect in the treat‐
ment of patients with OIBD [16,17]. The stool remains in the gut lumen for a longer time,
allowing greater absorption of fluid. Enhanced absorption combined with opioid inhibition
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of secretomotor neurons in the epithelium of the gut [18] leads to the stool becomes hard
and dry. In summary, OIBD is the consequence of reduced gastrointestinal motility, in‐
creased absorption of fluids from the gut and decreased epithelial secretion.
3. Dyspepsia
Dysfunction of the upper gastrointestinal tract (esophagus, stomach and duodenum) often
manifests as dyspepsia. Dyspepsia represents a constellation of symptoms rather than a sin‐
gle disease entity. Its diverse symptoms may be expressed as epigastric pain, anorexia,
belching, heartburn, bloating, nausea and vomiting, post–prandial fullness, early satiety,
and/or regurgitation [19].
Two types of dyspepsia may be diagnosed:
• Structural (organic) dyspepsia for which a structural change can be demonstrated, often due
to acid–related disease such as a gastric ulcer. In advanced cancer patients, symptoms
may arise from NSAID, corticosteroid and bisphosphonate administration.
• Functional dysmotility (non–ulcer dyspepsia) due to dysmotility and/or altered sensitivity of
the upper GI tract affecting the esophagus, stomach and duodenum. Esophageal and gas‐
troduodenal dysmotility can be differentiated.
In  cancer  patients,  it  may be  iatrogenic  (e.g.;  opioid–induced delayed gastric  emptying)
and associated with  disease-related complications  like  hepatomegaly  or  massive  ascites.
Furthermore,  paraneoplastic  visceral  autonomic  neuropathy seems to  play an important
role. Opioids and other drugs such as anticholinergics, tricyclic antidepressants, benzodia‐
zepines,  nitrates and calcium channel blockers may decrease lower esophageal sphincter
tone and lead to reflux (GERD) that would be aggravated secondarily by delayed gastric
emptying.  Gastric  secretory and motor activity may be also affected by chronic alcohol‐
ism, diabetes, uremia, anxiety and depression. Gastroparesis is a symptomatic chronic dis‐
order  characterized  by  impaired  gastric  emptying  in  the  absence  of  a  structural  cause.
This occurs as a component of paraneoplastic syndromes, most commonly in the course
of small cell lung, breast, ovarian cancer, Hodgkin disease or multiple myeloma. In addi‐
tion to opioid adversely affecting gastric emptying, other drugs such as anticholinergics,
neuroleptics or tricyclic  antidepressants can aggravate gastroparesis.  Meanwhile,  concur‐
rent conditions such as diabetes, prior gastric surgery, and neuromuscular disorders may
further impair gastric emptying. Lastly, gastric or pancreatic tumors can inflict a mechani‐
cal outlet obstruction.
Another component that might co-exist is gastroesophageal reflux disease (GERD) due to re‐
flux of gastric contents into the esophagus, causing mucosal damage and heartburn.
The prevalence of functional dyspepsia is high in the normal population (24–34%) and even
higher in cancer patients (70%) [20]. Opioids adversely affect the esophagus. This class of
drugs impairs esophageal inhibitory innervation and so induces spastic esophageal dysfunc‐
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tion while impairing lower esophageal relaxation, leading to swallowing difficulties (dys‐
phagia). Opioids also reduce the lower esophageal sphincter (LES) pressure, thereby
decreasing the barrier pressure between the stomach and the esophagus, producing acid-re‐
flux symptoms. This effect is reversed by naloxone. Opioids inhibit gastric emptying, a
product of enhanced gastric relaxation and heightened pyloric tone. This decrease in gastric
emptying results from both central and peripheral effects, although a peripheral µ–opioid
receptor mechanism is dominant. Opioid administration increases duodenal motility by
generating patterns of contractions resembling migrating motor complex (MMC) phase III
patterns. Endorphins in humans decrease antral phasic pressure activity and increase pylor‐
ic phasic pressure activity and induce MMC III–like bursts of contractile activity in the prox‐
imal gut followed by motor quiescence. Exogenous and endogenous opioids impair gastric
emptying [21, 22].
The evaluation of patients with functional dyspepsia and gastroparesis is based on a careful
history taking and physical examination that allow differentiating between functional and
structural dyspepsia and GERD. The symptoms of gastroparesis, as quantified by the Gas‐
troparesis Cardinal Symptom Index (GCSI), consists of 9 symptoms, each graded from 0
(none) to 5 (very severe), divided into 3 subscales: postprandial fullness/early satiety, nau‐
sea/vomiting, and bloating [23]. Upper endoscopy is usually needed to exclude mechanical
obstruction and to assess for mucosal lesions. It is recommended in patients with alarming
symptoms e.g.; those suspected for gastrointestinal bleeding. Endoscopy may be also con‐
ducted when symptoms develop with NSAIDs administration and when treatment with an‐
tisecretory drugs or antacids is unsuccessful. Blood tests assessing complete blood count
and biochemistry might be useful. An ultrasound or CT abdominal scan is helpful to assess
for cancer spread. In some patients, solid phase gastric scintigraphic emptying studies or
breath tests may be needed to confirm gastroparesis. Other investigations such as electro‐
gastrography, antroduodenal manometry are infrequently used in cancer patients.
4. Management of opioid–induced bowel dysfunction
4.1. The management of dyspepsia
a. Non–pharmacological measures
Treatment should be directed at cause of symptoms. Functional dyspepsia may be treated
with non–pharmacological measures and drugs. The former comprise explanation and edu‐
cation of patients and families. Advice on the diet may play an important role. Fatty foods
should be avoided as lipids impair gastric emptying, while lipids entering the duodenum
may aggravate impaired gastric accommodation and gastric hypersensitivity. Medications
that may cause dyspepsia (e.g. NSAIDs) should be discontinued when possible [24].
b. Pharmacological approach
Pharmacological treatment is usually needed. First-line therapy for dyspepsia is usually acid
suppression. Proton pomp inhibitors (PPIs) such as omeprazole, esomeprazole or pantopra‐
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zole are used once daily in doses 20–40 mg, best given 30 minutes before breakfast. In cancer
patients, prokinetic agents are commonly administered, aiming to counteract opioid–in‐
duced motility disorders.
Typically, metoclopramide is prescribed (commonly as 10 mg t.i.d.) for patients with func‐
tional dyspepsia, especially when symptoms arise from gastroparesis. Metoclopramide
works mostly in the upper GI tract through blocking dopaminergic receptors. As metoclo‐
pramide also acts centrally, its use is associated with the added risk of extra–pyramidal ef‐
fects, particularly in younger patients and children. Metoclopramide also inhibits the
cytochrome, CYP2D6 enzyme [25]. The most common adverse effects of metoclopramide are
restlessness, drowsiness and fatigue. Concomitant use of antidepressants, such as tricyclics,
selective serotonin reuptake inhibitors (SSRIs) and newer serotonin–noradrenalin reuptake
inhibitors (venlafaxine, duloxetine), may aggravate the adverse effects of metoclopramide
[26]. Extrapyramidal effects are unlikely to occur when using domperidone, which does not
cross blood–brain barrier [27]. Cisapride is a 5HT4 receptor agonist, affecting the entire GI
tract; however, its cardiotoxicity has limited use [28].
Itopride works through peripheral blocking dopaminergic receptors. It inhibits acetylcholi‐
nesterase and so increases acetylcholine levels. Itopride works through the whole GI tract. It
is devoid of activity at 5–HT4 and 5–HT3 receptors. Itopride is metabolized through monoox‐
idase system. Thus, it has no significant risk of pharmacokinetic interactions with other
drugs. Itopride does not cross blood–brain barrier and in consequence does not induce ex‐
trapyramidal effects. The dose usually equals 50 mg t. i. d. [29]
Prucalopride, a new prokinetic agent, is a highly selective 5HT4 receptor agonist that stimu‐
lates gut motility in vitro and in vivo. Prucalopride at 2–4 mg daily accelerates whole gut,
gastric, small bowel and colonic transit in constipated patients [30]. The recommended dose
is 1–2 mg once daily. Prucalopride is used in managing chronic constipation predominantly
in women, but has not been evaluated in gastroparesis as yet [31]. Treatment is usually well-
tolerated; typical adverse effects are headaches (present in 25–30% of treated patients), nau‐
sea (12–24%), abdominal pain or cramps (16–23%) and diarrhea (12–19%) [32]. Both itopride
and prucapolpride appear safe relative to cardiac function.
Linaclotide is a minimally absorbed peptide guanylate cyclase-C agonist that appears quite
effective for chronic constipation and the irritable bowel syndrome [33,34]. It looks promis‐
ing in the treatment of gastroparesis and so may have a role in OBID.
Lubiprostone, a bicyclic fatty acid derived from prostaglandin E1, acts by specifically acti‐
vating chloride channels on the apical aspect of gastrointestinal epithelial cells, producing a
chloride-rich fluid secretion. These secretions soften the stool, increase intestinal motility,
and so promote spontaneous bowel movements. Lubiprostone thus has value in treating
functional constipation.
4.2. Oral and rectal laxatives for Opioid-induced Bowel Dysfunction
General measures to be taken in patients with OIBD and OIC include the assessment and
applying prophylactic measures matched to the patient’s general condition [35]. Change of
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diet (increased food and fluid intake), more physical activity, assuming a sitting position
during bowel movement and obtaining privacy during defecation process are recommend‐
ed [36]. Patients treated with opioids should be considered for prokinetic administration
[37]. Any reversible causes such as hypercalcaemia should also be treated. Discontinuing or
decreasing doses of drugs that may aggravate constipation (e.g. tricyclics, neuroleptics, anti‐
cholinergics) should also be considered. Patients and families should be educated about the
means to prevent and treat OIBD [9].
In most patients with OIBD, laxatives are necessary. The general recommendation is to com‐
bine orally administered osmotic agents – usually lactulose or macrogol (PEG – polyethy‐
lene glycol) which have an osmotic effect in the colon [10] with stimulants activating on
neurons in the myenteric and submucosal plexus in colon and reducing absorption of water
and electrolytes from the intraluminal contents: anthracenes (senna), polyphenolics (bisa‐
codyl) or sodium picosulphate. Unfortunately, these drugs exhibit limited efficacy in pa‐
tients suffering from OIBD. Moreover, they may cause several adverse effects and must be
administered on a regular basis [38]. Other classes of laxatives are faecal lubricants (liquid
paraffin), stool softeners (surfactants: sodium docusate); however, they are usually ineffec‐
tive when administered alone [39]. The use of bulk–forming agents such as fibre, bran,
methylcellulose and psyllium seeds has limited role in patients with advanced constipation
and warrant ingesting adequate fluids (at least 2 liters per day) [40–42]. Castor oil is not rec‐
ommended due to its sudden stimulating effect on bowel motility and the risk of developing
severe abdominal cramps [43]. If oral laxatives are found to be ineffective, rectal treatment
should be considered.
Rectal laxatives comprise suppositories increasing intestinal motility through direct stimula‐
tion of the nerve endings in the myenteric ganglia of the colon, thus inducing peristalsis (bi‐
sacodyl) or using osmotic drugs (glycerol), which act by irritating the rectal mucosa and also
enhance the colonic motility that subsequently triggers the defecation reflex. The next step if
these agents prove ineffective is rectal enemas, either as normal saline (100–200 ml) or phos‐
phates (120–150 ml).
The management of faecal impaction depends on the severity of symptoms (rectal pain, ab‐
dominal colicky pain, protruding hard faeces and faecal leakage). If the symptoms are not
severe in case of soft faeces, administer bisacodyl 10–20 mg once daily either rectally or oral‐
ly until bowel movements are achieved. If hard faeces are present, use glycerol and bisacod‐
yl suppositories or osmotic enemas. Enemas of arachis oil (130 ml) or of decussate sodium
(100 ml) followed by a phosphate enema next day may be appropriate. Macrogol (PEG) re‐
duces the need for digital disimpaction. Digital stool evacuation may be necessary in cases
of severe symptoms, when neither oral nor rectal treatment gives a desired effect and faecal
impaction is not relieved, causing significant distress to the patient. As the procedure is
quite painful and distressing, it should be performed with great caution and only when nec‐
essary and sometimes necessitating intravenous sedation with midazolam combined with
opioids plus topical analgesics [44].
Polyethylene glycol (PEG) and sodium picosulphate are more effective than lactulose in OIC
in cancer pain patients [45]. PEG specifically appears to be more effective than lactulose in
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terms of weekly bowel movement frequency, patient satisfaction, ease of defecation and re‐
duced constipation symptoms with similar treatment tolerance and slightly higher lactulose
costs [46]. For palliative care patients, different laxative regimens have no real differences.
Overall, there is limited efficacy of traditional laxatives; well-done randomised controlled
trials are lacking [47].
4.3. Opioid switch
The possibility of opioid switch for OIBD should be considered as one of the available treat‐
ment options. Opioids, which seem to be more often associated with constipation, are co‐
deine and dihydrocodeine (opioids for mild to moderate pain), morphine, oxycodone and
hydromorphone (opioids for moderate to severe pain). These opioids may be switched to
other opioids belonging to the same group but having less constipating effect: codeine or di‐
hydrocodeine may be switched to tramadol; morphine, oxycodone or hydromorphone to
transdermal opioids (fentanyl, buprenorphine) or to methadone [48,49]. The most convinc‐
ing evidence supporting the benefits of the opioid switch as regards constipation relief
comes from the morphine to transdermal fentanyl switch [50–53]. In contrast to clinical stud‐
ies, observational surveys do not provide evidence for advantages of transdermal fentanyl
over other opioid analgesics with respect to bowel function. [54-55] Other studies report
similar or less intense constipating effects with transdermal buprenorphine compared to CR
morphine [56] and after a switch from morphine to methadone [57–59]. There may be a ben‐
efit to administering tramadol rather than small morphine doses [60–62] or dihydrocodeine
[63] with respect to the constipation intensity. However, no differences were found in con‐
stipation in cancer patients with pain between transdermal opioids (buprenorphine and fen‐
tanyl) and oral controlled release hydromorphone [64].
4.4. Targeted treatment of opioid–induced bowel dysfunction
Few clinical studies compared the efficacy of different laxatives [65] and controlled studies
are lacking [66]. Certainly traditional laxatives do not target the cause of OIBD, which is pre‐
dominantly associated with opioid analgesics binding and activating µ–opioid receptors in
the GI tract [67]. Treatment directed at the cause of OIBD involves either using a combina‐
tion of opioid analgesics with opioid receptor antagonists, which act both centrally and pe‐
ripherally, or administering opioid receptor antagonists, which act exclusively peripherally.
An important advantage of this approach is the fact that it is targeted treatment of OIBD and
that it may be combined with oral laxatives, if necessary. Finally, this approach may elimi‐
nate the need for rectal measures, which patients tolerate poorly.
Apart from opioid antagonists with exclusively peripheral effects, opioid receptor antago‐
nists with a central mode of action are naloxone, naltrexone and nalmefene. The majority of
studies performed so far have used immediate release formulation of oral naloxone (IR na‐
loxone). In spite of high IR naloxone efficacy in the treatment of OIBD, some patients experi‐
ence opioid withdrawal symptoms and attenuation of analgesia, rendering IR naloxone less
useful when administered alone [68–70]. Nalmefene [71] and nalmefene glucuronide [72] be‐
have similarly.
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4.5. Combined opioid receptor agonist with its antagonist
One  of  methods  to  decrease  the  frequency  of  constipation  in  patients  requiring  strong
opioids is using formulation composed of an opioid and opioid receptor antagonist. The
formulation combining oxycodone and naloxone is available in the form of prolonged re‐
lease (PR) tablets containing both drugs in the ratio of 2:1 (PR oxycodone/PR naloxone 5
mg/2.5  mg,  10 mg/5 mg,  20 mg/10 mg,  40 mg/20 mg) [73].  The optimal  2:1  ratio  of  PR
oxycodone/PR naloxone tablets was demonstrated in a phase II study rendering effective
analgesia and improvement in bowel function with good treatment toleration in patients
with severe chronic pain [74]. PR oxycodone/PR naloxone is registered for the indication
of severe pain, which may only be successfully treated with opioid analgesics. In this for‐
mulation,  naloxone  counteracts  the  development  of  OIBD  through  inhibition  of  oxyco‐
done  effect  on  opioid  receptors  in  the  gut  wall  [75].  The  starting  PR  oxycodone/PR
naloxone  doses  in  opioid–naive  patients  is  5  mg/2.5  mg  b.i.d.  Patients  unsuccessfully
treated with opioids for mild to moderate pain (tramadol, codeine, dihydrocodeine) may
start with the dose 10 mg/5 mg b.i.d. When rotating from other opioids for moderate to
severe  pain  to  PR oxycodone/PR naloxone,  the  starting  dose  is  established individually
depending on the  amount  of  previously  administered opioid,  analgesia  and adverse  ef‐
fects. The maximal daily dose of PR oxycodone/PR naloxone recommended equals 40 mg/
20 mg twice  daily.  However,  in  a  study conducted in  cancer  patients  with  pain higher
daily  doses  up  to  120  mg/60  mg were  effective  and  well–tolerated  while  symptoms  of
OIBD were decreased, compared to PR oxycodone administered alone [76].
Following oral administration, oxycodone displays high bioavailability (60 – 87%) and pro‐
vides effective analgesia [77,78]. Naloxone exhibits low bioavailability after oral administra‐
tion (< 2%) and undergoes extensive first–pass metabolism in the liver with the formation of
naloxone–3–glucuronide [79]. Analgesic effect is not reversed by naloxone and no symp‐
toms of opioid withdrawal occur. This effect of orally administered naloxone depends on
normal liver function. Thus, any hepatic impairment should be carefully considered. In pa‐
tients suffering from decompensated liver disease, PR oxycodone/PR naloxone administra‐
tion is not recommended. There is a clinically observed difference between the
administration of IR and PR formulations of naloxone. IR naloxone in some patients may at‐
tenuate analgesia or induce opioid withdrawal symptoms. The PR naloxone formulation
prevents saturation of hepatic enzyme system responsible for naloxone metabolism and re‐
duces the risk of opioid antagonism in the CNS [3].
PR oxycodone/PR naloxone provides similar analgesic efficacy to oxycodone with improve‐
ment in bowel function, a lower consumption of laxatives and more frequent spontaneous
bowel movements [82]. during treatment with PR oxycodone/PR naloxone in comparison to
PR oxycodone therapy [80–82]. Long–term therapy (up to 52 weeks) with PR oxycodone/PR
naloxone in daily doses up to 80 mg/40 mg appears effective and safe [83]. Analgesia is ef‐
fective while bowel function and quality of life improved with PR oxycodone/PR naloxone
(20 mg/10 mg to 40 mg/20 mg) treatment in patients with severe neuropathic non–malignant
pain [84]. Even at quite high doses, PR oxycodone/PR naloxone doses exhibited a benefit
compared to PR oxycodone administered alone [85]. PR oxycodone/PR naloxone in doses up
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to 120 mg/60 mg per day provides effective analgesia while improving bowel function [76].
Adverse effects of PR oxycodone/PR naloxone and PR oxycodone are similar; the frequency
of diarrhea is slightly higher in PR oxycodone/PR naloxone compared to PR oxycodone ad‐
ministered alone (5.2% vs. 2.6%) [81]. However, PR oxycodone/PR naloxone less frequency
induces nausea (6.3% vs. 10.5%), vomiting (1.3% vs. 4.3%), abdominal pain (1.3% vs. 4.3%)
and dyspepsia (0.6% vs. 2.5%) in comparison to PR oxycodone administered alone [82].
These differences might be explained by naloxone antagonist effect on gastric and gut
opioid receptors and in consequence, naloxone prokinetic properties [86]. PR oxycodone/PR
naloxone studies were performed mainly in patients with chronic, non–malignant pain [80–
83,85,89]. Opioid switch to PR oxycodone/PR naloxone for cancer patients generally pro‐
vides adequate analgesia and improved bowel function [87], but in some requiring height‐
ened analgesia, very high doses of PR up to 240 mg per day oxycodone administered alone
may be necessary[88].
The contraindications for PR oxycodone/PR naloxone comprise bowel obstruction, acute ab‐
dominal conditions, diarrhea and an allergy to the drug. PR oxycodone/PR naloxone is
available in several European countries. One pack contains 60 PR oxycodone/PR naloxone
tablets of 5 mg/2.5 mg, 10 mg/5 mg, 20 mg/10 mg, 40 mg/20 mg strength. Direct treatment
costs for PR oxycodone/PR naloxone in patients with moderate–to–severe non–malignant
pain and opioid–induced constipation is slightly higher compared to oxycodone PR. When
analysing constipation treatment costs and benefits of PR oxycodone/PR naloxone in terms
of improved quality–adjusted life–years, PR oxycodone/PR naloxone appears to be cost–ef‐
fective option in the UK [90]. Government and other insurance schemes however may not
reimburse PR oxycodone/PR naloxone tablets.
4.6. Purely peripherally acting opioid receptor antagonists
Methylnaltrexone (MNTX), a derivative of naltrexone, is a peripheral µ–opioid receptor an‐
tagonist, which does not cross blood–brain barrier [91]. Because of its low oral bioavailabili‐
ty, MNTX is administered subcutaneously or intravenously [92]. However, MNTX taken
orally prevents the delay in oro–ceacal transit time that follows intravenous morphine ad‐
ministration [93]. MNTX plasma half–life equals 105 to 140 minutes. 50% is excreted un‐
changed in the urine. MNTX is a weak CYP2D6 inhibitor with no significant drug
interactions [94]. MNTX is used to treat OIC in adult patients with advanced diseases when
constipation does not respond to conventional oral laxatives. The drug is available in am‐
poules containing 12 mg MNTX bromide in the volume of 0.6 ml and is applied via subcuta‐
neous injections. The recommended single MNTX dose is 8 mg in patients with body weight
38–61 kg or 12 mg if the body mass is 62–114 kg [95]. Those falling outside of this range
should receive a dose of 0.15 mg/kg. No dose adjustment is necessary for patients with mild
to moderate hepatic or renal impairment. However, in patients with severe renal failure
(creatinine clearance < 30 mL/min) the MNTX dose should be reduced by one–half [96].
A bowel movement within 4 h after MNTX injection is observed in 50–60% patients (the me‐
dian time to bowel movement after the drug administration is 30 minutes). If no therapeutic
effect is observed, the injection may be repeated every other day. MNTX adverse effects
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comprise abdominal pain (28% of the treated patients), flatulence (13%), nausea (11%), dizzi‐
ness (7%) and diarrhoea (5%) [16]. However, the administration of MNTX may be associated
with an increased risk of gastrointestinal perforation in patients with diseases that decrease
gut wall integrity (cancer, peptic ulceration and Ogilvie’s syndrome) or on concomitant
medications (NSAIDs, bevacizumab). GI perforation occur at different possible locations
(duodenum, small and large bowel). A possible contributing factor might be the prokinetic
effect of MNTX. It is not known if dose and duration of the treatment with MNTX relate to
this complication [95]. As MNTX does not cross the blood–brain barrier, there is no attenua‐
tion of analgesia nor is there an opioid withdrawal syndrome [17]. The use of MNTX is con‐
traindicated in patients with mechanical bowel obstruction, in acute abdominal conditions
and in case of allergy to the drug. MNTX may be used in palliative care patients with OIBD
not amenable to the treatment with oral laxatives. Several clinical studies have demonstrat‐
ed the effectiveness of MNTX in patients with advanced diseases and with OIBD
[16,17,95,96,98–100]. Peripherally active opioid receptor antagonists in the treatment of
OIBD are effective and safe in [101-4]. Long–term efficacy and safety of opioid antagonists is
not yet clearly established, in part due to a limited number of randomized studies [105-6].].
The Expert Working Group of the Polish Association for Palliative Medicine developed a
three step ladder for the management of OIC (Fig. 1) [43]. This updated version of the ladder
takes into account new therapies directed at the underlying mechanism of OIBD [107].
 
 
 
3 
 
 
 
2 
 
 
 
1 
       Drug(s) of step I (oral): 
 Osmotic agents: 
lactulose or macrogol 
 Stimulants: antranoids 
or poliphenolics 
 Oxycodone/naloxone 
      Drug(s) of step II: 
 Rectal suppositories 
 PAMORA* 
(Methylnaltrexone – sc) 
      Invasive procedures of step III:  
 Rectal enema 
 Manual evacuation** 
Constipation persists or intensifies
Constipation persists or intensifies
* PAMORA–peripherally acting mu–opioid receptor antagonists (methylnaltrexone) indicated for patients who do not
respond to traditional oral laxatives without bowel obstruction and acute abdominal illness; ** This procedure should
be used only when other measures fail and the faecal impaction causes significant pain and distress for the patient. It
should be proceeded by a sedative and analgesics (local and systemic) administration that provide effective relief of
severe pain and distress associated with manual stool evacuation; sc – subcutaneous
Figure 1. The three-step ladder of the management of opioid–induced constipation [43,107]
Dyspepsia - Advances in Understanding and Management192
At the first step traditional oral laxatives and/or PR oxycodone/PR naloxone may be consid‐
ered. PR oxycodone/PR naloxone targets the source of OIBD (prevention and treatment) as
PR naloxone blocks opioid receptors in the gut and PR oxycodone provides effective analge‐
sia. PR oxycodone/PR naloxone may be considered in cancer pain patients who are at high
risk of OIBD development such as those with GI tumors, patients who require combined
treatment with opioids and other drugs disturbing normal bowel function, e.g. advanced
cancer patients. At the second step subcutaneous administration of MNTX may be consid‐
ered when traditional oral laxatives are ineffective, which may allow avoiding invasive and
often painful invasive procedures at step 3 of the ladder.
5. Conclusions
OIBD in patients diagnosed with chronic diseases is a challenging problem that health care
providers often underestimate. This is particularly important in patients regularly receiving
opioids for pain or other indications. Thanks to newly introduced drugs that target the
cause of OIBD, a more effective therapy is available. The experience with MNTX and PR
oxycodone/PR naloxone in patients suffering from OIBD is promising. Further clinical stud‐
ies are needed to develop more effective guidelines for the management of OIBD and to es‐
tablish more precisely the role of opioid receptor antagonists. The role of opioid receptor
antagonists as potential antiemetic and prokinetic agents should be further explored as sug‐
gested by experimental studies in animals. The cost-benefit from new therapies must be
carefully considered; overall resources may actually be saved from reduced use of tradition‐
al laxatives. The most important advantage of targeted therapies is to decrease patient suf‐
fering from OIBD, substantial reduce the need to perform invasive rectal procedures and
most importantly, improve quality of life.
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